SES
15.5.2019 08:57:05 CEST | Business Wire | Press release
Dream Cruises, a brand of Genting Cruise Lines, has selected SES Networks’ Signature Cruise Solution to provide exceptional speeds, low latency, and unmatched fibre-like service to its passenger ship fleet, comprised of World Dream, Genting Dream and Explorer Dream, for the Asian luxury market, SES announced today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190514005969/en/
Crew and guests of the newly-launched Explorer Dream will experience exceptional SES-powered guest connectivity onboard the 75,000-gross-ton, 2,000-passenger ship. The SES Networks’ solution will also be introduced onboard Genting Dream in September this year, completing the fleet-wide implementation that follows the successful launch of SES Networks’ managed service onboard World Dream, Dream Cruises’ second cruise ship, which debuted in 2017.
The new Explorer Dream will have homeports in Shanghai and Tianjin, as well as Sydney and Auckland later in the year. Its significantly enhanced connectivity will enable guests to chat with friends on WeChat, pick up a bargain on Taobao, or stream high-resolution video on YouKu without interruption or lag. It will also mean that guests can share photos and videos from their trip in real-time across social media, or battle with their friends in League of Legends as easily as they can on land.
SES Networks’ Signature Cruise Solution combines the low latency of its O3b medium earth orbit (MEO) satellite constellation with a fully managed end-to-end service, backed up by its highly reliable geostationary (GEO) fleet to ensure network resilience. The result is a seamless, high-performance broadband service delivered to everyone onboard the Dream Cruises fleet.
“Today’s cruise passengers demand excellent connectivity even when they are travelling on the high seas. As part of our efforts to provide our guests with the best possible services and amenities on board our ships, we partnered with SES Networks because of their high-speed capability to deliver a terrestrial broadband-like internet experience in some of the most challenging of conditions,” said Thatcher Brown, President at Dream Cruises.
"A Dream Cruise has the ability to deliver inspirational voyages at sea that create memories to last a lifetime. A key part of that adventure nowadays is the digital experience. Our Signature Cruise Solution ensures that passengers onboard Explorer Dream – along with World Dream and Genting Dream – will experience the new standard of enhanced guest connectivity,” said Simon Maher, Vice President Global Sales, Cruise Maritime Services at SES Networks. “Because SES Networks and Dream Cruises have shared values around delivering transformational and inspirational experiences at sea, we are incredibly proud to partner with them to enable this level of service.”
Follow us on:
Social
Media
Blog
Media
Gallery
White
Papers
About SES
SES is the world’s leading satellite operator with over 70 satellites in two different orbits, Geostationary Orbit (GEO) and Medium Earth Orbit (MEO). It provides a diverse range of customers with global video distribution and data connectivity services through two business units: SES Video and SES Networks. SES Video reaches over 355 million TV homes, through Direct-to-Home (DTH) platforms and cable, terrestrial, and IPTV networks globally. The SES Video portfolio includes MX1, a leading media service provider offering a full suite of innovative services for both linear and digital distribution, and the ASTRA satellite system, which has the largest DTH television reach in Europe. SES Networks provides global managed data services, connecting people in a variety of sectors including telecommunications, maritime, aeronautical, and energy, as well as governments and institutions across the world. The SES Networks portfolio includes GovSat, a 50/50 public-private partnership between SES and the Luxembourg government, and O3b, the only non-geostationary system delivering fibre-like broadband services today. Further information is available at: www.ses.com
About Genting Cruise Lines
Genting Cruise Lines is a division of Genting Hong Kong comprising of three distinct cruise brands – Star Cruises, Dream Cruises and Crystal Cruises – providing a range of products from contemporary cruises to ultra-luxurious vacation experiences spanning the sea to air.
Established in 1993, Star Cruises is the pioneer in the Asia Pacific cruise industry currently with a fleet of six ships catering to the contemporary market segment. As “The Most Popular Cruise Line in Asia”, Star Cruises will further expand its footprint in the region with the delivery of two new “Global Class” ships, each measuring 201,000 gross tons, in 2020 and 2021.
“Asia’s Luxury Cruise Line”, Dream Cruises delivers the highest level of guest service and spacious comfort in the region via newly launched Genting Dream (November 2016) and the upcoming World Dream (late 2017). Developed for the high-end consumers in China and Asia, Dream Cruises will provide passengers with more choice, comfort and value to create a perfect dream voyage.
Crystal Cruises is “The World’s Most Awarded Luxury Cruise Line”, having earned more “World’s Best” awards than any other cruise line, hotel, or resort in history. Recently, Crystal has embarked on a significant brand expansion introducing two new classes of cruising – Crystal Yacht Cruises and Crystal River Cruises – and reaching new heights with Crystal Luxury Air and Crystal AirCruises.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190514005969/en/
Contact:
Suzanne Ong Public Relations Tel. +352 710 725 500 suzanne.ong@ses.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom